SHIMMER

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 26, 2024
Research, Corporation, Conference, DLB, Alzheimer's disease, Disease, Biomarker, Public expenditure, Translational Neurodegeneration, Completeness, Vance DeGeneres, Protein, Clinical trial, Quantitative electroencephalography, Therapy, NIA, SHIMMER, Cognition, Pharmaceutical industry

PURCHASE, N.Y., March 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. Management will host a live webcast conference call at 8:00am ET to review 2023 accomplishments. Details of the call are provided below.

Key Points: 
  • ET -
    PURCHASE, N.Y., March 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • Cognition scientists published two manuscripts and made 11 presentations at medical and scientific congresses in 2023, advancing the understanding of its foundational science and clinical implications.
  • “We achieved a number of critical clinical objectives in 2023,” said Lisa Ricciardi, Cognition’s president and CEO .
  • Management will host a conference call and live webcast to discuss Cognition’s financial results today at 8:00 a.m.

Cognition Therapeutics CEO Issues Letter to Shareholders

Retrieved on: 
Thursday, January 4, 2024
Biology, Work, Geographic atrophy, SHIMMER, Alzheimer's disease, Dementia, Neuron, ACTC, Iris (anatomy), EEG, Lewy body, RPE, Antibody, Letter, AMD, Brain, Therapy, Clinical trial, ADAS, SPARC, Society, DLB, SHINE, Cognition, Vance DeGeneres, Biomarker, Toxicity, Optimism, Manuscript, Cell, Patient, Magnification, Synapse, Diagnosis, Safety, Pharmaceutical industry

PURCHASE, N.Y., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today announced that CEO Lisa Ricciardi has issued a Letter to Shareholders to provide an update on recent pipeline developments and a preview of the company’s strategy in 2024. The full text of the letter follows:

Key Points: 
  • PURCHASE, N.Y., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today announced that CEO Lisa Ricciardi has issued a Letter to Shareholders to provide an update on recent pipeline developments and a preview of the company’s strategy in 2024.
  • The full text of the letter follows:
    The year ahead holds great promise for Cognition Therapeutics.
  • As we work towards these important milestones, we take stock of the achievements that give rise to optimism at Cognition Therapeutics and in the broader medical community.
  • For Cognition, expanding the pipeline for CT1812 to dry AMD has the potential to grow Cognition’s value across multiple age-related diseases.

Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 2, 2023
Research, NIA, SHIMMER, Public expenditure, SHINE, DLB, Dementia, Lewy body, Cognition, Therapy, Patient, SEQUEL, Vaccine, Pharmaceutical industry

PURCHASE, N.Y., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today reported financial results for the third quarter ended September 30, 2023 and provided recent business updates.

Key Points: 
  • The Company estimates that it has sufficient cash to fund operations and capital expenditures through November of 2024.
  • Research and development expenses were $11.7 million for the third quarter ended September 30, 2023, compared to $8.3 million for the same period in 2022.
  • General and administrative expenses for the third quarter ended September 30, 2023, were $3.1 million compared to $4.4 million for the three months ended September 30, 2022.
  • The decrease was primarily related to lower professional fees, Director & Officer Liability insurance partially offset by increased equity-based compensation.

Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

Retrieved on: 
Tuesday, August 8, 2023
Retina, Vance DeGeneres, Central nervous system, SHIMMER, Quantitative electroencephalography, SPARC, AMD, CMC, NIA, Geographic atrophy, Cognition, DLB, Cell, ID, Public expenditure, Dementia, Baozou Big News Events, Lilly, Canadian International Council, Donanemab, Synapse, Lewy body, CFO, Webcast, Research, Therapy, Death, BLA, News, SEQUEL, SHINE, Pharmaceutical industry, Eisai

PURCHASE, N.Y., Aug. 08, 2023 (GLOBE NEWSWIRE) --  Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today reported financial results for the second quarter ended June 30, 2023 and provided recent business updates.

Key Points: 
  • PURCHASE, N.Y., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today reported financial results for the second quarter ended June 30, 2023 and provided recent business updates.
  • We anticipate full study results to be available in the fourth quarter of 2023.
  • Research and development expenses were $8.5 million for the second quarter ended June 30, 2023, compared to $9.1 million for the same period in 2022.
  • ET, to discuss the second quarter corporate and financial update.

First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812

Retrieved on: 
Thursday, December 15, 2022
Degenerative disease, Czech, Head, Intellectual property, ADAS, Clinical trial, Czech Republic, Synapse, Vance DeGeneres, Autophagy, Biogen, Antibody, Eisai, Safety, Retina, Central nervous system, Traffic barrier, Risk, DLB, Dementia, Neuron, Government budget balance, Securities & Exchange Commission of Pakistan, Biomarker, NIA, SHIMMER, Therapy, MRI, Oxidative stress, Lewy body, SHINE, COVID-19, Patient, Pharmaceutical industry, Medical device, Medical imaging, Cognition

This new mechanism of action is fundamentally distinct from and complementary with that of anti-amyloid antibody-based immunotherapy, such as lecanemab.

Key Points: 
  • This new mechanism of action is fundamentally distinct from and complementary with that of anti-amyloid antibody-based immunotherapy, such as lecanemab.
  • However, unlike antibodies, which lower brain amyloid levels, CT1812 was designed to shield neurons from these toxic proteins.”
    Results from initial trials with CT1812 provided evidence to support expansion of the clinical programs.
  • CT1812 is an oral small molecule designed to penetrate the blood-brain barrier and bind selectively to the sigma-2 (σ-2) receptor complex.
  • We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD).

Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD

Retrieved on: 
Monday, November 28, 2022
Lewy, COVID-19, Pathology, National Institute on Aging, Patient, Dementia, Head, University, DLB, Synapse, Cognition, Therapy, Brain, Degenerative disease, Sleep, Retina, Protein, Anxiety, Central nervous system, SHIMMER, LBDA, Lewy body, Behavior, Hallucination, Intellectual property, Risk, Vance DeGeneres, NIA, Lewy Body Dementia Association, Delusion, Securities & Exchange Commission of Pakistan, MPH, Neuron, Safety, Pharmaceutical industry, MD

The Phase 2 SHIMMER (COG1201) study is intended to assess the safety, tolerability, and efficacy of CT1812 in individuals with dementia with Lewy bodies (DLB).

Key Points: 
  • The Phase 2 SHIMMER (COG1201) study is intended to assess the safety, tolerability, and efficacy of CT1812 in individuals with dementia with Lewy bodies (DLB).
  • The SHIMMER study is being conducted at over 30 sites in the United States, many of which are LBDA centers of excellence.
  • DLB is caused by a build-up of a protein, -synuclein, which forms deposits, called Lewy bodies, in the brain.
  • We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimers disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD).

Cognition Therapeutics Launches Neuroscience Thought Leader Conversations Podcast/Webinar Series

Retrieved on: 
Monday, November 21, 2022
COVID-19, Dementia, Diagnosis, University, DLB, Therapy, Degenerative disease, Retina, Epidemiology, Central nervous system, Cognition, SHIMMER, Research, Lewy body, Family, Intellectual property, Risk, Vance DeGeneres, NIA, Lewy Body Dementia Association, MPH, Securities & Exchange Commission of Pakistan, Biology, Body, Pharmaceutical industry, Medicine

PURCHASE, N.Y., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (Nasdaq: CGTX), (the Company or Cognition) has introduced a new podcast/webinar series named Conversations, that will feature virtual fireside chats with neuroscience experts to discuss advances in the research and treatment of Alzheimers disease, dementia with Lewy bodies (DLB), and other age-related neurodegenerative conditions.

Key Points: 
  • PURCHASE, N.Y., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (Nasdaq: CGTX), (the Company or Cognition) has introduced a new podcast/webinar series named Conversations, that will feature virtual fireside chats with neuroscience experts to discuss advances in the research and treatment of Alzheimers disease, dementia with Lewy bodies (DLB), and other age-related neurodegenerative conditions.
  • Cognition Therapeutics invites researchers to listen in on this and future Conversations at www.cogrx.com/conversations and learn more about the most common dementia, no one has heard of.
  • Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina.
  • More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com/
    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.

Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 14, 2022
National Institute on Aging, DLB, Philadelphia Managing Director's Office, SHIMMER, Retina, Degenerative disease, Securities & Exchange Commission of Pakistan, Dementia, Risk, Therapy, Cognition, NIA, AAIC, Private law, Biomarker, Supplement, Inflammation, Intellectual property, Vance DeGeneres, Czech Republic, Central nervous system, Neuron, COVID-19, Research, SHINE, Lewy body, Pharmaceutical industry, Lease, SEQUEL

PURCHASE, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) --  Cognition Therapeutics, Inc. (Nasdaq: CGTX), (the “Company” or “Cognition”) today reported financial results for the third quarter ended September 30, 2022 and provided an update on the company’s business and clinical development progress.

Key Points: 
  • PURCHASE, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), (the Company or Cognition) today reported financial results for the third quarter ended September 30, 2022 and provided an update on the companys business and clinical development progress.
  • The increase for 2022 was primarily attributable to an increased phase 2 trial activity, personnel costs, and preclinical program expenses.
  • General and administrative expenses for the third quarter ended September 30, 2022 were $4.4 million compared to $1.6 million in 2021.
  • Net loss attributable to common stockholders for the third quarter ended September 30, 2022, was $6.6 million or $0.29 per share.

Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.

Retrieved on: 
Wednesday, October 12, 2022
Lewy body, Therapy, Diagnosis, Degenerative disease, Delusion, Vance DeGeneres, Lewy, Hallucination, Private Securities Litigation Reform Act, Retina, Patient, Sleep, MPH, Mental health, NIA, Dementia, Nasdaq, Awareness, Risk, LBD, University, Neurology, Lewy Body Dementia Association, Neuron, U.S. Securities and Exchange Commission, National, Â, Securities & Exchange Commission of Pakistan, SHIMMER, Safety, Cognition, DLB, GLOBE, Neurodegeneration, Brain, Intellectual property, Practitioner, Pathology, Central nervous system, Biomarker, Pharmaceutical industry, Medicine, MD

The Phase 2 SHIMMER study ( NCT05225415 ) is actively recruiting participants for these sites across the United States, including those that are Lewy Body Dementia Association centers of excellence added Anthony O. Caggiano, M.D., Ph.D., Cognitions chief medical officer and head of R&D.

Key Points: 
  • The Phase 2 SHIMMER study ( NCT05225415 ) is actively recruiting participants for these sites across the United States, including those that are Lewy Body Dementia Association centers of excellence added Anthony O. Caggiano, M.D., Ph.D., Cognitions chief medical officer and head of R&D.
  • This month is Lewy Body Dementia Awareness month with approximately over 1.4 million people in the United States suffering from the neurodegenerative disease, making it the second most common form of dementia.
  • Often misdiagnosed it also masks itself as Parkinsons disease and is the largest dementia most have never heard of.
  • This October, during Lewy Body Dementia Awareness Month, lets recommit to educating ourselves about LBD.

Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, August 9, 2022
Lewy body, Intellectual property, Risk, Private Securities Litigation Reform Act, CEO, RPE, Dementia, Trial of the century, GLOBE, DLB, SPARC, National Institute, AAIC, SHINE, Research, Public expenditure, SHIMMER, Patient, Therapy, Cell, COVID-19, Company, Alzheimer's disease, Central nervous system, National Institute on Aging, Degenerative disease, ACTC, AMD, Neurodegeneration, NASDAQ, Securities & Exchange Commission of Pakistan, U.S. Securities and Exchange Commission, Retinal, ARVO, Retina, Philadelphia Managing Director's Office, Pharmaceutical industry, Lease, Cognition

PURCHASE, N.Y., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) (the “Company” or “Cognition”), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina, today reported financial results for the second quarter ended June 30, 2022 and provided recent business updates.

Key Points: 
  • The second quarter of 2022 has been characterized by optimistic advancements in our clinical trials and compelling data presentations, said Lisa Ricciardi, president and CEO of Cognition.
  • Presented data at ARVO 2022 conference held in May 2022 suggesting favorable acting mechanism of CT1812 for the treatment of dry AMD.
  • Research and development expenses for the second quarter ended June 30, 2022 were $9.1 million compared to $4.9 for the same period in 2021.
  • Net loss attributable to common stockholders for the second quarter ended June 30, 2022, was $5.8 million, or $(0.25) per share.